Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A post hoc FIDELITY analysis suggests finerenone improves cardiovascular and kidney outcomes across CKM stages and may modestly shift patients toward CKM regression over time.
CRISPR-engineered GGTA1/B4GALNT2/SLA-DR knockout pigs remained healthy, screened negative for 55 zoonotic pathogens, and supported long-term renal xenograft function in rhesus monkeys when preformed anti-SLA antibodies were absent.
In a nationwide U.S. analysis of 21,010 adult DCD kidney transplants, normothermic regional perfusion lowered delayed graft function, shortened hospital stay, and improved graft and patient survival, with the greatest benefit in higher-risk
Higher proteinuria in preeclampsia was linked to greater long-term risk of maternal hypertension and chronic kidney disease, with overall increased risk of cardiovascular disease as well.
In a pre-specified exploratory analysis of SURPASS-CVOT, tirzepatide reduced major kidney events versus dulaglutide in people with type 2 diabetes and cardiovascular disease, mainly by lowering new macroalbuminuria and slowing eGFR decline.
Higher CKM syndrome stages correlate with adverse cardiac remodeling and increased heart failure risk in older adults, as shown in the ARIC Study.
Early low-calorie and low-protein nutrition in critically ill patients with shock does not worsen renal outcomes compared to standard feeding, per NUTRIREA-3 post hoc analysis.
In a phase 2 randomized trial, OCE-205 improved HRS-AKI in more patients than placebo and showed no excess ischemic or respiratory toxicity, but the study was underpowered after early termination.
A 14-year cohort study of 3,079 individuals with type 1 diabetes reveals that visit-to-visit blood pressure variability, particularly systolic blood pressure variability measured by average real variability, significantly predicts diabetic
This review synthesizes recent evidence on the massive scale of CKM medication eligibility in the US, the synergistic effects of pharmacotherapy with lifestyle, and emerging neuropsychiatric benefits of GLP-1 receptor agonists.
A longitudinal study using Latent Class Analysis identifies four distinct phenotypes of T2D patients developing CKD, highlighting young-onset and middle-aged low-comorbidity groups as primary drivers of healthcare costs.
This review analyzes a latent class trajectory study identifying four clinical phenotypes of T2D-related CKD, revealing that young-onset patients incur the highest longitudinal healthcare costs.
This review synthesizes evidence comparing SGLT2 inhibitors and GLP-1 receptor agonists, highlighting a significant reduction in chronic kidney disease and acute kidney injury risks associated with SGLT2i initiation.
A large-scale retrospective study in Ontario indicates that solid-organ transplant recipients, particularly kidney transplant patients, experience significantly better outcomes for emergency general surgery conditions when treated at specia
This study evaluates HbA1c, glycated albumin, and fructosamine against CGM in dialysis patients. While HbA1c and glycated albumin show strong correlations with mean glucose, significant clinical biases from ESA use, BMI, and dialysis modali
A landmark 35-year analysis of DCCT/EDIC data demonstrates that a reduced estimated glomerular filtration rate (30–90 mL/min/1.73 m2) is not an independent risk factor for diabetic ketoacidosis, providing a clearer safety framework for the
A multicenter study of 680 Fabry disease patients reveals that age, renal function, QRS duration, and left ventricular mass are critical independent predictors of major adverse cardiovascular events, highlighting persistent unmet needs desp
A post hoc analysis of the CRHCP trial demonstrates that intensive blood pressure control (<130/80 mmHg) significantly reduces major adverse **Confirming JSON Structure** I’m now fully focused on creating the JSON object. I’v
The Phase 3 VISIONARY trial interim analysis demonstrates that sibeprenlimab, a monoclonal antibody targeting APRIL, significantly reduces proteinuria and pathogenic IgA1 in patients with IgA nephropathy, offering a promising upstream thera
A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.
Open language-specific specialty feeds and department pages.